Recursion Pharmaceuticals is a buy for its innovative AI-driven drug discovery platform that uses automation, imaging, and machine learning to uncover new therapeutic opportunities at an unprecedented scale.
Source Post
2 Biotech Stocks That Could Explode as AI Drug Discovery Lifts Off
Mar 15, 2026
The video discusses two biotech stocks, Eli Lilly (LLY) and Recursion Pharmaceuticals (RXRX), that are poised to benefit from AI-driven drug discovery. Eli Lilly is highlighted for its scale, execution, and ability to commercialize breakthroughs, while Recursion is presented as an innovator building a new operating system for drug discovery using automation and machine learning.
Linked Mentions
Tickers discussed in this post
Eli Lilly is a buy due to its global scale, deep scientific expertise, and proven ability to execute and commercialize drug discoveries, making it a strong player in the AI-driven biotech era.